Literature DB >> 35651452

A Rare Case of Hereditary Hemorrhagic Telangiectasia: A Case Report.

Ahmad R Khan1, Salma Waqar1, Muhammad Hayyan Wazir1, Amina Arif1.   

Abstract

Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a very rare autosomal dominant genetic disorder that leads to abnormal blood vessel formation in the skin, mucus membranes (called telangiectasia), and organs such as the lung, liver, and brain. It occurs due to a mutation in one of the ACVRL1, ENG, and SMAD4 genes, which code for the formation of blood vessels. The most common symptom is recurring nosebleed (epistaxis; due to rupture of nasal mucosal telangiectasia), which begins in childhood and affects about 90-95% of people with HHT. Other common signs and symptoms include punctate, linear, or splinter-like telangiectasias on the upper body, oral mucosa, or nail beds, gastrointestinal bleeding, and iron deficiency anemia. The diagnostic criteria currently in use are the Curaçao criteria. The diagnosis is made by clinical screening (e.g., history and physical exam), baseline investigations (complete blood count, hemoglobin, hematocrit, and ferritin level), genetic testing, and detailed medical imaging to detect visceral arteriovenous malformations (AVMs) such as esophagogastroduodenoscopy, colonoscopy, multiphase contrast CT, computed tomography angiography (CTA or CT Angio), magnetic resonance angiography (MRA), chest X-ray, Doppler ultrasonography, liver biopsy, and cerebral angiography. Management includes intravenous iron therapy or blood transfusion, antifibrinolytics (e.g tranexamic acid), ablation therapies (e.g. laser treatment, radiofrequency ablation, electrosurgery, sclerotherapy, and argon plasma coagulation), and systemic anti-angiogenic agents (e.g. thalidomide, bevacizumab). In this report, we present the case of a 22-year-old man from Swabi, Pakistan, with a history of recurrent epistaxis (nosebleed) from childhood, who presented with multiple episodes of melena (blood in stool), fatigue, palpitation, and iron deficiency anemia for five years. Multiple esophagogastroduodenoscopies (OGDs) and colonoscopies were done over the years, which showed AVM in the antrum and fundus of the stomach, duodenum, and colon, and a diagnosis of HHT was made. CTA and exploratory laparotomy showed ileal loop hemangiomas. He was managed with multiple blood transfusions, argon plasma coagulation (APC) for the AVMs, oral thalidomide, and steroids. Despite therapy, the patient had intermittent episodes of blood in stool and low blood counts. During his stay in Hayatabad Medical Complex (HMC), the patient was managed with high-frequency blood transfusion and bevacizumab (systemic anti-angiogenic agent). A dramatic reduction in the number of required transfusions and improvement in the patient's bloodlines and symptoms was noted. This case highlights the importance of endoscopic methods for the timely diagnosis of HHT and its management with intravenous bevacizumab.
Copyright © 2022, Khan et al.

Entities:  

Keywords:  hereditary hemorrhagic telangiectasis; melena; osler-weber-rendu syndrome; pulmonary avm; recurrent gi bleeding

Year:  2022        PMID: 35651452      PMCID: PMC9136551          DOI: 10.7759/cureus.24517

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  13 in total

Review 1.  Hereditary hemorrhagic telangiectasia: from molecular biology to patient care.

Authors:  S Dupuis-Girod; S Bailly; H Plauchu
Journal:  J Thromb Haemost       Date:  2010-03-19       Impact factor: 5.824

2.  Combined juvenile polyposis and hereditary hemorrhagic telangiectasia.

Authors:  Jane-Claire B Williams; J Kent Hamilton; Michelle Shiller; Laurice Fischer; Gregory Deprisco; C Richard Boland
Journal:  Proc (Bayl Univ Med Cent)       Date:  2012-10

3.  A hereditary haemorrhagic telangiectasia family with pulmonary involvement is unlinked to the known HHT genes, endoglin and ALK-1.

Authors:  G M Wallace; C L Shovlin
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

4.  Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome).

Authors:  C L Shovlin; A E Guttmacher; E Buscarini; M E Faughnan; R H Hyland; C J Westermann; A D Kjeldsen; H Plauchu
Journal:  Am J Med Genet       Date:  2000-03-06

5.  Endovascular treatment of epistaxis: indications, management, and outcome.

Authors:  Katharina Strach; Andreas Schröck; Kai Wilhelm; Susanne Greschus; Henriette Tschampa; Markus Möhlenbruch; Claas P Naehle; Mark Jakob; Andreas O H Gerstner; Friedrich Bootz; Hans H Schild; Horst Urbach
Journal:  Cardiovasc Intervent Radiol       Date:  2011-04-07       Impact factor: 2.740

6.  The prevalence and manifestations of hereditary hemorrhagic telangiectasia in the Afro-Caribbean population of the Netherlands Antilles: a family screening.

Authors:  Cornelius J J Westermann; Ahlsen F Rosina; Vanessa De Vries; Pamela A de Coteau
Journal:  Am J Med Genet A       Date:  2003-02-01       Impact factor: 2.802

7.  Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia.

Authors:  Marie E Faughnan; Johannes J Mager; Steven W Hetts; Valerie A Palda; Kelly Lang-Robertson; Elisabetta Buscarini; Erik Deslandres; Raj S Kasthuri; Andrea Lausman; David Poetker; Felix Ratjen; Mark S Chesnutt; Marianne Clancy; Kevin J Whitehead; Hanny Al-Samkari; Murali Chakinala; Miles Conrad; Daniel Cortes; Claudia Crocione; Jama Darling; Els de Gussem; Carol Derksen; Sophie Dupuis-Girod; Patrick Foy; Urban Geisthoff; James R Gossage; Adrienne Hammill; Ketil Heimdal; Katharine Henderson; Vivek N Iyer; Anette D Kjeldsen; Masaki Komiyama; Kevin Korenblatt; Jamie McDonald; Jack McMahon; Justin McWilliams; Mary E Meek; Meir Mei-Zahav; Scott Olitsky; Sara Palmer; Rose Pantalone; Jay F Piccirillo; Beth Plahn; Mary E M Porteous; Marco C Post; Ivan Radovanovic; Paul J Rochon; Josanna Rodriguez-Lopez; Carlo Sabba; Marcelo Serra; Claire Shovlin; Dennis Sprecher; Andrew J White; Ingrid Winship; Roberto Zarrabeitia
Journal:  Ann Intern Med       Date:  2020-09-08       Impact factor: 25.391

Review 8.  Hereditary haemorrhagic telangiectasia: a clinical and scientific review.

Authors:  Fatima S Govani; Claire L Shovlin
Journal:  Eur J Hum Genet       Date:  2009-04-01       Impact factor: 4.246

Review 9.  Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): new insights in pathogenesis, complications, and treatment.

Authors:  T Haitjema; C J Westermann; T T Overtoom; R Timmer; F Disch; H Mauser; J W Lammers
Journal:  Arch Intern Med       Date:  1996-04-08

Review 10.  Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis.

Authors:  Jamie McDonald; Pinar Bayrak-Toydemir; Reed E Pyeritz
Journal:  Genet Med       Date:  2011-07       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.